Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Total Non-Current Liabilities (2016 - 2025)

Traws Pharma (TRAW) has disclosed Total Non-Current Liabilities for 12 consecutive years, with $7.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Non-Current Liabilities changed N/A to $7.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $7.9 million, a N/A change, with the full-year FY2024 number at $14.1 million, changed N/A from a year prior.
  • Total Non-Current Liabilities was $7.9 million for Q3 2025 at Traws Pharma, up from $7.4 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $14.1 million in Q4 2024 to a low of $7.4 million in Q2 2025.
  • A 3-year average of $10.7 million and a median of $11.0 million in 2021 define the central range for Total Non-Current Liabilities.
  • Biggest YoY gain for Total Non-Current Liabilities was 4.84% in 2021; the steepest drop was 11.99% in 2021.
  • Traws Pharma's Total Non-Current Liabilities stood at $10.9 million in 2021, then grew by 29.88% to $14.1 million in 2024, then plummeted by 44.06% to $7.9 million in 2025.
  • Per Business Quant, the three most recent readings for TRAW's Total Non-Current Liabilities are $7.9 million (Q3 2025), $7.4 million (Q2 2025), and $12.9 million (Q1 2025).